Global renal disease treatment devices market is expected to grow at rapid pace due to rising incidences of chronic kidney disorders (CKD) and end stage renal disease (ESRD). Rising patient base of hypertension and lifestyle associated diseases are the major reasons behind increasing kidney related diseases which are expected to drive the demand for treatment devices during forecast period. Increasing geriatric population base is also one of the key driver for this market as ageing is the common factor responsible for increasing incidences of renal diseases. As per WHO report of 2011, more than 190 million people were suffering from chronic kidney disorders and 220 million males were suffered from diseases of prostate glands worldwide is anticipated to grow progressively over the decade. This rising incidence rate of renal diseases has shifted doctor’s preferences towards use of advanced renal disease treatment devices enabling reduced treatment and recovery time. Other market drivers such as improvising healthcare infrastructure, introduction of novel therapies in renal disease treatment devices especially in developed countries are expected to boost the market over the forecast period. Development of safe and effective novel therapies for renal disease treatment is contributing growth of this market. Technological advancement such as point of care drug delivery systems and growing emphasis on maintaining quality of life are the factors promoting growth of this market. Additionally, increasing R&D expenditures, supportive government policies and increasing usage of personalized medicines are further expected to fuel the market growth of renal disease treatment device market over the forecast period.
The overall market is segmented on the basis of treatment and devices. Treatment procedures for renal diseases include hemodialysis dialyzers and kidney transplant. Hemodialysis dialyzer accounted for one of the largest market share as of 2014, owing to its extensive usage by ESRD patients. On the basis of types of devices market segmented into devices for urinary stone treatment, dialysis, pelvic organ prolapsed treatment, endoscopy, benign prostatic hyperplasia treatment devices, prostatic stents, lithotripsy, sacral neuromodulation, urethral inserts & pessaries, urethral stents, vaginal meshes & slings, peritoneal dialysis, catheter ablation and urinary stone treatment. Dialysis segment held the largest market share due to rising incidences of CKD. A peritoneal dialysis catheter is less costly than other dialysis treatments and expected to use on large scale by patients.
On the basis of geography, market is segmented into North America, Asia Pacific, Latin America, Middle East Asia and Europe. North America was the largest revenue generating market in 2014 owing to the presence of sophisticated healthcare facilities and supportive government policies. In the U.S. new prospective payment system was initiated on January 1, 2011, named ESRD reimbursement system. This system combines the payments for dialysis, drugs and lab tests into one single payment to control the cost of dialysis treatments which expected to drive the market at rapid pace. Increasing adoption of technologically advance devices especially in the hospitals, fueling the growth of the U.S. market during forecast period. European market, owing to rising geriatric population database and prevalence of chronic diseases is expected to drive the demand for renal disease treatment devices. Increasing healthcare expenditure, untapped opportunities and government funding for R&D in Asia pacific region is expected to drive the regional renal disease treatment device market during forecast period. Emerging economies such as India and China are major contributors to the growth of Asia Pacific market.
Key market players studied are Fresenius Medical Care, Dornier Medtech, Baxter International, C.R. Bard, Asahi Kasei Corp., Jolla Pharmaceutical Company, Terumo Corporation and B Braun Group. Companies are adopting competitive strategies such as new product development, collaborations, merger & acquisitions and partnerships. Baxter international acquired Gambro (Sweden) in September 2013, in an attempt to extend its dialysis product portfolio and market penetration in European market. Similarly, ongoing research by La Jolla Pharmaceutical Company shows positive results for phase II clinical trial on novel drug such as GSC-100 drug molecule in CKD are also expected to drive the growth of renal disease treatment devices market.
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.